Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MITOMYCIN”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,009 records · Page 56Linked to original sources
PubMed1999

UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.

A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer. Mitomycin was administered intravenously at 13 mg/m2 on the day of surgery. Patients judged to be ER-positive were randomly allocated to either group A, which received oral tamoxifen 20 mg/day 14 days after surgery for 2 years, or group B, receiving oral UFT 400 mg/day plus tamoxifen 20 mg/day. A total of 219 patients were enrolled in group A, of which 213 (97.3%) were determined to be eligible; 225 patients enrolled in group B and 223 (99.1%) were eligible. The 5-year survival rates were 93.0% for group A and 95.4% for group B, with no significant difference between groups. The 5-year relapse-free survival rates were 83.1% for group A and 90.7% for group B, a significant advantage (P = .020) for the UFT plus tamoxifen group. Combination therapy with mitomycin, tamoxifen, and UFT proved to be an effective postoperative chemoendocrine therapy for stage II, ER-positive breast cancer.

Adult↗
PubMedDate not supplied

Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma.

The aim of the study was to evaluate the therapeutic activity and safety of continuously infused (c.i.) mitomycin C in patients with metastatic gastrointestinal adenocarcinomas recurring after or progressing during chemotherapy. The patients were treated with mitomycin C 20 mg/m2 intravenously over a time period of 120 hours, followed by a 3-week rest. Seventy-eight patients were entered into the study. All the patients were assessable for toxicity and 72 for response evaluation, having completed at least one full course of chemotherapy. Among 52 colorectal cancer patients one single objective response (2%) was observed. Disease stabilisation was achieved in 11 patients (23%). Median survival time was 4.7 months (CI95%, 1.9 to 8.6). In 20 evaluable patients with gastric cancer, one complete and 5 partial remissions were observed [ORR: 30% (CI95%, 9.1-50.9%)]. The median response duration was 2.1 months (range, 2 to 6), and the median survival time 3.6 months (CI95%, 2.1 to 6.0). WHO degree III/IV mucositis, diarrhea and fever/infection each occurred in 6% of the patients. Thrombo- and leukocytopenia (WHO degree III/IV) occurred in 19% and 6% of the patients, respectively. Mitomycin C has some single-agent activity in advanced gastric cancer but no substantial efficacy was seen as in heavily pretreated colorectal carcinoma.

Adenocarcinoma↗
PubMed2000

Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.

PURPOSE: We evaluated alternatives to bacillus Calmette-Guerin (BCG) monotherapy using a new combination of chemotherapy and immunotherapy for recurrent superficial bladder carcinoma. MATERIALS AND METHODS: A total of 236 patients with frequently recurrent stage Ta or T1 bladder tumors were enrolled in our prospective, randomized, multicenter Finnbladder IV study. The initial mitomycin C instillation was instilled in all patients perioperatively after transurethral resection, followed by 4 weekly instillations of mitomycin C. Thereafter patients were randomized to receive monthly for up to 1 year BCG only or interferon-alpha2b and BCG alternating monthly. Primary end points were time to initial recurrence, recurrence rate (number of recurrences per patient-year) and recurrence index (number of recurrent tumors per patient-year). RESULTS: Of the 236 randomized patients 205 were eligible for study with a median overall followup of 30.7 months. Monthly BCG was superior to alternating monthly interferon-alpha and/or BCG with respect to time to initial recurrence (log rank test p <0.00001) as well as recurrence rate (0.4 versus 0.9, p <0.00001) and index (0.9 versus 3.0, p <0.00001). Side effects were limited. CONCLUSIONS: Monthly BCG given for up to 1 year preceded by perioperative and an additional 4 weekly mitomycin C instillations is a well tolerated mode of instillation therapy, providing excellent tumor control comparable to that of the best reported instillation regimens. No benefit was obtained by alternating interferon-alpha2b with BCG.

Adjuvants, Immunologic↗
PubMedDate not supplied

Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.

BACKGROUND: Thirteen-cis retinoic acid (RA) has been shown to have growth-inhibitory and differentiative activity on non-small cell lung cancer (NSCLC) cells in vitro. This promoted the rationale for combining RA with three active drugs, cisplatin (CDDP) vindesine (VDS) and mitomycin-c (MMC) in the treatment of advanced NSCLC. PATIENTS AND METHODS: Patients with a histologically confirmed non-resectable NSCLC, measurable lesion, performance status < or = 3, and informed consent were enrolled. The chemotherapy schedule included cisplatin 60 mg/m2 and mitomycin-c 10 mg/m2 day 1 and vindesine 3 mg/m2 on days 1 and 5, every 4 weeks. RA was administered orally, at a dose of 0.5 mg/kg, 5 days per week, during chemotherapeutic intervals and to responding patients until disease progression was observed. RESULTS: Thirty patients, receiving a total of 163 chemotherapy courses, were evaluated for response and toxicity. Objective responses included complete response in 2 patients (7%), partial response in 10 patients (33%), stable disease in 9 patients (30%) and progressive disease in 9 patients (30%), (response rate 40%: Confidence interval 95% 22.7% to 59.4%). Median time to progression was 8.6 months (range 3.9-45+). Median overall survival was 11.3 months (range 1-45+). The 1-year survival rate was 47%. Toxicity (WHO) included nausea and vomiting grade 2 in 6 patients, transient ileus in 3 patients and grade 3-4 leukopenia in 5 patients. Two patients underwent surgical resection of residual disease and remain in CR. CONCLUSIONS: The addition of RA to cisplatin, vindesine and mitomycin-c is feasible and shows some activity in the treatment of NSCLC, with manageable toxicity.

Adult↗
PubMedDate not supplied

Hepatic arterial infusion for liver metastases from colon cancer: comparison of mitomycin C(NSC-26980) and 5-fluorouracil (NSC-19893).

This study compares the effectiveness of hepatic arterial infusion of mitomycin C with that of 5-fluorouracil in the management of carcinoma of the colon metastatic to the liver. A higher tumor response rate was obtained with 5-FU (ten of 12 patients) than with mitomycin C (six of 13 patients). The patients treated with mitomycin C had a median survival time of 9.5 months compared to 12 months for those receiving 5-FU, but this survival is not much different from that of the untreated historical controls. Femoral artery thrombosis requiring surgical thrombectomy developed in five of the 30 catheterized patients.

Adenocarcinoma↗
PubMed2000

UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.

UFT is an investigational agent that may be useful treatment for colorectal carcinoma and other cancers for which fluorinated pyrimidines are a useful treatment. The combination of continuous-infusion fluorouracil (5-FU) with leucovorin and mitomycin-C can significantly delay recurrence and may prolong life. UFT may be an attractive alternative to continuous-infusion 5-FU because three-times-daily administration of UFT results in comparable concentrations of 5-FU in the plasma. Recently, a clinical trial investigated the combination of UFT and mitomycin-C and found it demonstrated significant synergy in the treatment of advanced colorectal cancer. We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer.

Adult↗
PubMed1998

[Application of mitomycin C in glaucoma filtration surgery].

OBJECTIVE: To investigate the efficacy and the complication of glaucoma filtration surgery with intraoperative mitomycin C. METHODS: Between April 1994 and February 1996, 33 eyes of 28 patients underwent filtration procedures with intraoperative mitomycin C. Then a follow up of mean 6.65 months (range, 1-12 months) was taken. RESULTS: The Class I success rate was 72.7% when the intraocular pressure (IOP) was less or equal to 2.79 kPa without glaucoma medicine. The Class II success rate was 24.2% when the IOP was controlled with topical glaucoma medicine. In the postoperative period, persistant hypotony developed in 4 eyes, and hypotony-related maculopathy developed in 2 of these eyes. No conjunctival wound leak and endophthalmitis was present. CONCLUSIONS: Intraoperative mitomycin C in glaucoma filtration surgery can increase the success rate, while it is associated with a higher incidence of complications such as hypotony.

Adolescent↗
PubMedDate not supplied

Hyperbaric oxygen therapy for mitomycin C-induced scleral necrosis.

Intraoperative or postoperative use of mitomycin C is one of the treatment options to reduce the recurrence of pterygia. Scleral necrosis, a potentially blinding complication after mitomycin C use, has been among great concern in ophthalmic practice. A patient is presented in whom scleral necrosis developed 20 days after a pterygiectomy with bare sclera technique was performed, followed by the application of 0.4 mg/mL of topical mitomycin C eye drops for 3 weeks. After conjunctival flap failures the patient was treated with hyperbaric oxygen therapy. The sclera revascularized and returned to near normal thickness after 24 sessions of hyperbaric oxygen therapy. This case demonstrates that it is an effective, novel treatment. [Ophthalmic

Adult↗
PubMedDate not supplied

Hyperbaric oxygen therapy for mitomycin C-induced scleral necrosis.

Intraoperative or postoperative use of mitomycin C is one of the treatment options to reduce the recurrence of pterygia. Scleral necrosis, a potentially blinding complication after mitomycin C use, has been among great concern in ophthalmic practice. A patient is presented in whom scleral necrosis developed 20 days after a pterygiectomy with bare sclera technique was performed, followed by the application of 0.4 mg/mL of topical mitomycin C eye drops for 3 weeks. After conjunctival flap failures the patient was treated with hyperbaric oxygen therapy. The sclera revascularized and returned to near normal thickness after 24 sessions of hyperbaric oxygen therapy. This case demonstrates that it is an effective, novel treatment. [Ophthalmic

Adult↗
PubMedDate not supplied

Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.

A 28-year-old man underwent pterygium excision with a single intraoperative application of mitomycin C (0.02%) for 3 minutes. One week after the surgery, the patient developed a corneoscleral perforation with iris prolapse. To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported. Moreover, the perforation occurred despite using a minimum concentration of the drug, risk factors were absent, and the surgery was performed by an experienced surgeon. Although a single case, this report questions the safety of using an intraoperative application of mitomycin C for preventing a recurrence of pterygium.

Adult↗
PubMed2003

[Immune response of dendritic cells acquiring antigens from apoptotic cholangiocarcinoma cells induced by mitomycin].

OBJECTIVE: To investigate the anti-tumor immune response of dendritic cells (DCs) acquiring antigens from apoptotic cholangiocarcinoma cells and their therapeutic effects on cholangiocarcinoma cells. METHODS: DCs from human peripheral blood monocytes which acquired antigen capturing and processing capacity, characteristics of maturation, were established in vitro using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). Then cholangiocarcinoma cells were induced to apoptosis with mitomycin. The three groups included (1) coculture of DCs, apoptotic cancer cells and T cells, (2) coculture of DCs, necrotic cancer cells and T cells, (3) coculture of DCs, cultured cancer cells and T cells. After 7 days, DCs and T cells were riched separately to perform anti-tumor cells test and immune response test. RESULTS: these cells had typical dendritic cell morphology, expressed high levels of CD1a and B7, acquired antigen from apoptotic cells caused by mitomycin and could stimulate T cells to inhibit, even kill cholangiocarcinoma cells. CONCLUSIONS: The DCs from peripheral blood monocytes induced by GM-CSF and IL-4 can efficiently present antigen derived from apoptotic cells caused by mitomycin, and stimulate T cells activity obviously. It maybe become an effective therapy for tumor.

Antigens, Neoplasm↗
PubMedDate not supplied

Evaluation of limbal conjunctival autograft and low-dose mitomycin C in the treatment of recurrent pterygium.

BACKGROUND AND OBJECTIVE: To assess the effectiveness of limbal conjunctival autograft and low-dose mitomycin C in the treatment of recurrent pterygium. PATIENTS AND METHODS: Thirty-four eyes with recurrent pterygium underwent surgical excision followed by the intraoperative application of low-dose (0.05%) mitomycin C and the use of limbal conjunctival autograft. All patients were observed for at least 18 months for any complications, including recurrences. RESULTS: Neither recurrences nor serious complications were recorded. Visual acuity improved significantly (P < .05) in eyes with pterygium extending 3 mm or more beyond the limbus. CONCLUSION: Simple excision and low-dose mitomycin C followed by limbal conjunctival autograft is a safe and effective way of treating recurrent pterygium.

Adult↗
PubMed2003

[Prospective randomized trial of prophylaxis of postoperative peritoneal carcinomatosis of advanced gastric cancer: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles].

OBJECTIVE: To evaluate the beneficial effect of intraperitoneally applied mitomycin bound to activated carbon particles (MMC-CH) in the prevention and treatment of intraabdominal recurrence after curative surgery for gastric cancer. METHODS: One hundred and twenty-four patients with radically resected gastric cancer infiltrating the serosal surface were randomly divided into group receiving 50 mg mitomycin bound to a solution of 375 mg carbon adsorbent intraperitoneally before closure of the abdominal wound (n = 62) and a control group (n = 62). The patients with MMC-CH and the control group were received systemic chemotherapy 3 months or 3 weeks after operation respectively. The postoperative recurrence-free survival was evaluated to analyze the benefits of this treatment. RESULTS: After observation for 8 months (range, 2 - 65). The 3-, 5-year postoperative recurrence-free survival rates were significantly higher in the MMC-CH group (70.16%, 44.51%) than in the control group (27.09%, 14.45%), P < 0.01. CONCLUSION: Adjuvant intraperitoneal chemotherapy of gastric cancer by mitomycin bound to activated carbon particles is effected by an increased postoperative recurrence-free survival rate.

Antibiotics, Antineoplastic↗
PubMed1992

[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].

We observed the effects of intravesical irrigation with BCG (group B), Mitomycin-C (group M), and Thiotepa (group T) in prophylaxis of bladder tumor recurrence after surgical treatment. Follow-up for 1-10 years showed that the recurrence rate of bladder tumor was 12.5% (3/24) in group B, 46.9% (15/33) in group M, and 61.8% (21/34) in group T respectively. The effect of BCG was far better than that Mitomycin-C and Thiotepa (P < 0.01). In 5 cases, who failed to Thiotepa, also showed satisfactory results after use of intravesical BCG. Considering the side-effects of intravesical BCG, Thiotepa or Mitomycin-C should be used as the first choice of drugs in preventing the tumor recurrence.

Administration, Intravesical↗
PubMed1992

[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].

One hundred and three patients previously treated with chemotherapy including an anthracycline were entered in a VMMC protocol study: vindesine (Eldisine), mitoxantrone (Novantrone) and mitomycin C (Ametycine). Group A consisted of 41 women who received the protocol published by Belpomme: vindesine (2.5 mg/m2 day 1 and 8) and mitoxantrone (12 mg/m2/day) every 4 weeks, and mitomycin C (8 mg/m2) every 8 weeks. Group B consisted of 62 patients who were treated with a modified protocol: vindesine (2.5 mg/m2) and mitoxantrone (12 mg/m2) every 3 weeks on day 1, and mitomycin C (8 mg/m2) every 6 weeks. Tolerance was acceptable with 79% of patients complaining of weakness. There was a 66% incidence of gastro-intestinal toxicity, a 10.7%-incidence of neurotoxicity (reversible dysethesias), and a 5.8% incidence of cardiotoxicity. There was considerable hematotoxicity of grade 2, 3 and 4: neutropenia 16.6%, thrombocytopenia 7.7%, anemia 21.4%. There was a 19.2% overall objective response rate (CR and PR) (95% confidence interval: 12-30) (CR: 3.2%). The median duration of the response was 39 weeks. There was no significant difference in response rates whether or not the patients (19 cases) were undergoing simultaneous hormonal therapy and no difference according to the protocol used. Similarly, neither menopause nor a previous response to anthracyclines had any effect on the response rate. The 19.2% response in this protocol is similar to other breast cancer salvage chemotherapy protocols for patients who have failed to respond to anthracyclines (< 20%).

Adult↗
PubMed1992

Mitomycin C and aminoglutethimide in the treatment of metastatic prostatic cancer: a phase II study.

In a phase II study, 24 patients with metastatic prostatic cancer were treated with mitomycin C 15 mg/m2 i.v. every 6 weeks, combined with aminoglutethimide 250 mg twice a day. A low dose of 37.5 mg cortisone acetate was supplied daily to compensate for adrenal cortical suppression. A partial response was demonstrated in 4 of 24 evaluable patients with bi-dimensionally measurable metastases. Stable disease occurred in 8 patients over a period of more than 6 months. Within the maximum cumulative dose limit of 2 mg/kg body weight mitomycin C, toxicity was observed in 21 cases, including 2 deaths due to treatment toxicity. The poor response rate and high toxicity suggest that the addition of aminoglutethimide does not enhance the effect of mitomycin C in these patients.

Aged↗
PubMed2004

Fornix vs limbus based flap in phacotrabeculetomy with mitomycin C: prospective study.

AIM: To compare the efficacy and safety of fornix-based and limbus-based conjunctival flaps of phacotrabeculectomy with mitomycin C in patients with primary open angle glaucoma and cataract. METHODS: The study included 16 patients (6 men and 10 women) with primary open angle glaucoma and bilateral cataract. In each patient, phacotrabeculectomy with mitomycin C was performed on both eyes: the eye first operated received a fornix-based conjunctival flap, whereas the fellow eye was assigned to the limbus-based group. We compared preoperative and postoperative visual acuity, intraocular pressure, number of antiglaucoma medications, and postoperative complications between flap-based and limbus-based groups. RESULTS: There was no difference in the decrease in the mean intraocular pressure between the fornix-based and limbus-based groups after phacotrabeculectomy: from 22.1+/-4.4 mm Hg to 16.2+/-3.4 mm Hg in the fornix-based group, and from 22.4+/-4.5 mm Hg to 15.9+/-3.2 mm Hg in the limbus-based group. The two groups also did not differ in the number of medications received either before or after the surgery. Early bleb leak was observed only in the fornix-based group (2 eyes). CONCLUSIONS: Phacotrabeculectomy with intraoperative mitomycin C was successful in regard to both reduction of intraocular pressure and glaucoma medications. There was no difference in the safety or efficacy of the procedure between groups receiving either fornix- or limbus-based flap, except for the early bleb leak, which was observed only in the fornix flap group.

Aged↗
PubMedDate not supplied

Intermediate-term results of Baerveldt tube shunt surgery with mitomycin C use.

BACKGROUND AND OBJECTIVE: To study the intermediate-term results of the Baerveldt glaucoma drainage device with adjunctive use of intraoperative mitomycin C. PATIENTS AND METHODS: Charts of 243 consecutive patients with advanced glaucoma who had undergone tube shunt surgery between 1992 and 1999 were retrospectively analyzed. A total of 64 patients were eligible for the study. Patients were observed for a mean of 34.3 +/- 21 months. Kaplan-Meier survival analysis was used to determine intermediate-term success. RESULTS: The mean preoperative intraocular pressure (IOP) was 34.4 mm Hg and the 1-year postoperative IOP was 16.6 mm Hg. The mean percent IOP reduction after surgery was 51.7%, 53.2%, and 51.4% at 1, 2, and 5 years, respectively. Kaplan-Meier analysis showed a 77% success rate at 1 year, 66% at 2 years, and 59% at 5 years. The most common complication was choroidal detachment (18.8%). CONCLUSION: The use of mitomycin C with Baerveldt implantation showed IOP control equivalent to that without mitomycin C at intermediate follow-up.

Adult↗